deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03768505

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

Sponsor: MEI Pharma, Inc.

Conditions Follicular Lymphoma (FL) Marginal Zone Lymphoma Non Hodgkin Lymphoma
Interventions Zandelisib (ME-401)
Updated 37 times since 2019 Last updated: Dec 29, 2024 Started: Jun 25, 2019 Primary completion: Mar 24, 2023 Completion: Mar 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

discontinuation of zandelisib program

Other terminated trials from MEI Pharma, Inc.

More terminations from MEI Pharma, Inc.

Other Follicular Lymphoma (FL) trials with similar outcome

Browse all Follicular Lymphoma (FL) trials

A PHASE2 clinical study on Follicular Lymphoma (FL) and Marginal Zone Lymphoma, this trial is terminated or withdrawn. The trial is conducted by MEI Pharma, Inc. and has accumulated 37 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Feb 2022 · 9 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

37 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE2

  3. Feb 2025 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Terminated PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

▶ Show 32 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  2. Jun 2023 — Mar 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  6. Apr 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  7. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  8. May 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  9. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  10. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  12. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  14. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  15. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  16. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  17. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  18. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  19. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  20. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  21. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  22. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  23. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  24. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  25. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  26. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  27. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  28. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  29. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  30. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  31. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  32. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MEI Pharma, Inc.
Data source: MEI Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Ann Arbor, United States , Auckland, New Zealand , Aviano, Italy , Barcelona, Spain , Basking Ridge, United States , Bayonne, France , Belfast, United Kingdom , Bellinzona, Switzerland , Beverly Hills, United States and 86 more locations